Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Depreciation and Depletion (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Depreciation and Depletion for 4 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion fell 5.12% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.9 million, a 4.94% decrease, with the full-year FY2024 number at $13.3 million, up 1.99% from a year prior.
  • Depreciation and Depletion was $3.1 million for Q3 2025 at Century Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $3.6 million in Q4 2023 to a low of $1.2 million in Q1 2022.
  • A 4-year average of $3.0 million and a median of $3.2 million in 2025 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 150.69% in 2023, then dropped 7.54% in 2025.
  • Century Therapeutics' Depreciation and Depletion stood at $2.8 million in 2022, then rose by 25.16% to $3.6 million in 2023, then decreased by 6.59% to $3.3 million in 2024, then decreased by 5.7% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Depreciation and Depletion are $3.1 million (Q3 2025), $3.2 million (Q2 2025), and $3.2 million (Q1 2025).